Showing 3531-3540 of 6035 results for "".
- Robert Califf Confirmed to Lead FDA for Second Timehttps://modernod.com/news/robert-califf-confirmed-to-lead-fda-for-second-time/2480645/The US Senate on Tuesday voted 50 to 46 in favor of confirming President Joe Biden nominee Robert Califf as commissioner of the FDA, a position he previously held under the Obama administration, according to a FiercePharma report.&
- Maintaining Transparency: Study to Focus on Causes of Cataractshttps://modernod.com/news/maintaining-transparency-study-to-focus-on-causes-of-cataracts/2480616/Researchers at the University of Arizona College of Medicine – Tucson are leading a study to identify the biological mechanisms that cause cataracts in the hopes that new, nonsurgical treatments may be developed. Nicholas Delame
- Tarsus Appoints José Trevejo, MD, PhD, Chief Medical Officerhttps://modernod.com/news/tarsus-appoints-jose-trevejo-md-phd-chief-medical-officer/2480613/Tarsus Pharmaceuticals announced the appointment of José Trevejo, MD, PhD, as Chief Medical Officer. Dr. Trevejo brings over 20 years of experience advancing the clinical development of novel therapeutics for serious diseases. Dr. Trevejo’s leadership will be highly valued
- AI Can Identify Heart Disease From an Eye Scanhttps://modernod.com/news/ai-can-identify-heart-disease-from-an-eye-scan/2480602/Scientists have developed an artificial intelligence system that can analyze eye scans taken during a routine visit to an optician or eye clinic and identify patients at a high risk of a heart attack, according to a University of Leeds, UK, news release. Doctors have recognized th
- MeiraGTx Receives Clinical Development Milestone Payment from Janssenhttps://modernod.com/news/meiragtx-receives-clinical-development-milestone-payment-from-janssen/2480599/MeiraGTx Holdings announced that it has received a $30 million payment from Johnson & Johnson's Janssen Pharmaceuticals for a clinical milestone in the phase 3 Lumeos trial of botaretigene sparoparvovec (AAV-RPGR), an investigational gene therapy for the treatment of X-linked retinit
- Pixium Vision Announces the Publication of Peer-Reviewed Clinical Data Demonstrating the Clinical Benefit of the Prima System in Dry AMD Patientshttps://modernod.com/news/pixium-vision-announces-the-publication-of-peer-reviewed-clinical-data-demonstrating-the-clinical-benefit-of-the-prima-system-in-dry-amd-patients/2480597/Pixium Vision SA announced the publication of a paper in Nature Communications outlining further data with its Prima System, a photovoltaic substitute of photoreceptors providing simultaneous use of the central prosthetic and peripheral natural vision in atrophi
- Nanoscope Therapeutics Announces FDA Clearance of IND for MCO-010 Gene Therapy in Stargardt Macular Degeneration Patientshttps://modernod.com/news/nanoscope-therapeutics-announces-fda-clearance-of-ind-for-mco-010-gene-therapy-in-stargardt-macular-degeneration-patients/2480594/Nanoscope Therapeutics announced it received IND clearance from the FDA to begin a phase 2 trial of its Multi-Characteristic Opsin (MCO-010) ambient-light activatable optogenetic monotherapy to restore vision in Stargardt patients. “This is another important milestone for Nanoscop
- Researchers Define Keys to Recognizing Ocular Rosaceahttps://modernod.com/news/researchers-define-keys-to-recognizing-ocular-rosacea/2480589/A pair of new studies help establish the relative prevalence of signs and symptoms of the eyes of rosacea patients (ocular rosacea), as well as the importance of
- Several Changes Made in Leadership of Allergan Eye Carehttps://modernod.com/news/several-changes-made-in-leadership-of-allergan-eye-care/2480578/
- Kubota Vision Initiates PBOS Prospective Study in Patientshttps://modernod.com/news/kubota-vision-initiates-pbos-prospective-study-in-patients/2480577/Kubota Vision announced that on January 17, 2022, the first patient has enrolled and completed the first visit in a prospective study in Japan using the company's Patient Based Ophthalmology Suite (PBOS), in-home optical coherence tomography (OCT) device. The study is being led by S